Abuse deterrent formulations of opioid medications (ADOs) may help curtail the widespread abuse, misuse, and diversion of these products.With the exception of oxycodone, little information exists regarding the impact of abuse deterrent products on reducing abuse/misuse of opioid products.Studies have shown that Medicaid patients are dispensed opioids at a higher rate, abuse opioids at a higher rate, and experience more morbidity and mortality than other populations. In this study we seek to quantify misuse, abuse, dependence, and health resource use in a Medicaid patient sample prescribed an abuse deterrent formulation of extended release morphine (EMBEDA®) or non-abuse deterrent extended release morphine (ERM).
Pain Studies at PRA Early Development Services
PRA Health Sciences offers a range of pain models to assess pain perception and the efficacy of experimental analgesics in healthy volunteers and…
Sleep Hygiene, “Coronasomnia,” and Future Treatments
Read on to learn why regular sleep is so important and how the biopharma industry is addressing gaps in available insomnia therapies.
A Blueprint to Success: Onboarding a Medical Writer
Onboarding is the process of welcoming new employees into an organization and providing them with the tools, resources, and knowledge to become…